FEATURED/ARCHIVES (05/05/24)
What Is the Clinical Effectiveness and Cost-Effectiveness of Cytisine Compared with Varenicline for Smoking Cessation? A Systematic Review and Economic Evaluation · May 2014
Publications (Books-Reports)
National Institute for Health Research
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease (Review of TA111): A Systematic Review and Economic Model · April 2012
Publications (Books-Reports)
National Institute for Health Research
Extended-Release Injectable Naltrexone (Incorporating Alcohol Pharmacotherapies Into Medical Practice-Treatment Improvement Protocol) · January 2009
Publications (Chapters)
NCBI>Substance Abuse and Mental Health Services Administration
Administration of Naloxone in a Home or Community Setting: A Rapid Qualitative Review · December 2019
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Opioid Dependence: Buprenorphine Prolonged-Release Injection (Buvidal) · February 2019
Publications (Books-Reports)
National Institute for Health and Care Excellence
Practical Tools for Prescribing and Promoting Buprenorphine in Primary Care Settings · December 2021
Publications (Books-Reports)
Substance Abuse and Mental Health Services Administration
Cost-Effectiveness of Varenicline, Bupropion and Nicotine Replacement Therapy for Smoking Cessation · May 2010
Publications (Books-Reports)
NCBI>Norwegian Institute of Public Health
Randomised Controlled Trials of Conventional Antipsychotic versus New Atypical Drugs, and New Atypical Drugs versus Clozapine, in People with Schizophrenia Responding Poorly to, or Intolerant of, Current Drug Treatment · May 2006
Publications (Books-Reports)
National Institute for Health Research
Clonidine for the Treatment of Psychiatric Conditions and Symptoms: A Review of Clinical Effectiveness, Safety, and Guidelines · February 2018
Publications (Guidelines)
Canadian Agency for Drugs and Technologies in Health
Amisulpride for Adults with Refractory Schizophrenia: A Review of the Clinical Effectiveness and Safety · June 2011
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Acamprosate (Incorporating Alcohol Pharmacotherapies Into Medical Practice-Treatment Improvement Protocol) · January 2009
Publications (Chapters)
NCBI>Substance Abuse and Mental Health Services Administration
Health Economic Evaluation of Venlafaxine, Duloxetine, Bupropion, and Mirtazapine Compared to Further Prescribable Pharmaceutical Treatments · December 2009
Publications (Books-Reports)
Institute for Quality and Efficiency in Health Care
Aripiprazole for Borderline Personality Disorder: A Review of the Clinical Effectiveness · February 2017
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Vortioxetine for Treating Major Depressive Episodes · November 2015
Publications (Guidelines)
National Institute for Health and Care Excellence
Guanfacine Hydrochloride Extended-Release for Attention Deficit Hyperactivity Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines · March 2018
Publications (Guidelines)
Canadian Agency for Drugs and Technologies in Health
Naltrexone in Combination with Acamprosate for the Treatment of Alcohol Dependence: A Review of the Clinical and Cost-Effectiveness · October 2009
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Guanfacine Hydrochloride Extended-Release for the Treatment of Attention Deficit Hyperactivity Disorder in Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines · September 2018
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Guanfacine for Autism Spectrum Disorder, Attention-Deficit/Hyperactivity Disorder, and/or Oppositional Defiance Disorder · July 2022
Publications (Books-Reports)
Canadian Agency for Drugs and Technologies in Health
Sublingual and Transmucosal Buprenorphine for Opioid Use Disorder: Review and Update · March 2016
Publications (Books-Reports)
Substance Abuse and Mental Health Services Administration
Lithium or an Atypical Antipsychotic Drug in the Management of Treatment Resistant Depression: A Systematic Review and Economic Evaluation · November 2013
Publications (Books-Reports)
National Institute for Health Research